XML 57 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Development, Commercialization and Supply Agreement - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2021
USD ($)
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Item
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
License And Collaboration Agreements [Line Items]                            
Revenue recognized related to upfront and milestone payments                   $ 1,592,000 $ 5,691,000      
Licenses revenue               $ 142,038,000 $ 156,499,000 438,696,000 446,809,000      
Deferred revenue               17,132,000 18,905,000 17,132,000 18,905,000 $ 18,632,000   $ 20,846,000
Product Revenue, Net                            
License And Collaboration Agreements [Line Items]                            
Licenses revenue               141,442,000 155,190,000 $ 436,598,000 441,118,000      
Mochida Pharmaceutical Co., Ltd. | In-licenses                            
License And Collaboration Agreements [Line Items]                            
Milestones payment $ 1,000,000.0                     1,000,000.0    
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense                            
License And Collaboration Agreements [Line Items]                            
Upfront payment                         $ 2,700,000  
Edding | Out-licenses                            
License And Collaboration Agreements [Line Items]                            
Non-refundable up-front received             $ 15,000,000.0              
Number of indications of the regulatory milestone events relating to the submission and approval | Item                   3        
Amounts to be received upon achievement of the regulatory milestone events               33,000,000.0   $ 33,000,000.0        
Sales-based milestone event payment               120,000,000.0   120,000,000.0        
Revenue recognized related to upfront and milestone payments                   800,000 2,200,000      
Deferred revenue               10,000,000.0   10,000,000.0   10,800,000    
Edding | Out-licenses | Licensing Revenue                            
License And Collaboration Agreements [Line Items]                            
Licenses revenue                   6,900,000   6,100,000    
Edding | Out-licenses | Maximum                            
License And Collaboration Agreements [Line Items]                            
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone               153,000,000.0   153,000,000.0        
Amounts to be received upon achievement of the regulatory milestone events               15,000,000.0   15,000,000.0        
Sales-based milestone event payment               50,000,000.0   50,000,000.0        
Edding | Out-licenses | Minimum                            
License And Collaboration Agreements [Line Items]                            
Amounts to be received upon achievement of the regulatory milestone events               2,000,000.0   2,000,000.0        
Sales-based milestone event payment               5,000,000.0   5,000,000.0        
Edding | Out-licenses | Clinical Trial Application                            
License And Collaboration Agreements [Line Items]                            
Non-refundable milestone payment received           $ 1,000,000.0                
Biologix FZCo | Out-licenses                            
License And Collaboration Agreements [Line Items]                            
Revenue recognition period of non-refundable up-front payment           10 years                
Biologix FZCo | Out-licenses | Product Revenue, Net                            
License And Collaboration Agreements [Line Items]                            
Licenses revenue               500,000 500,000 1,000,000.0 500,000      
HLS | Out-licenses                            
License And Collaboration Agreements [Line Items]                            
Non-refundable up-front received         $ 5,000,000.0                  
Non-refundable milestone payment received   $ 2,500,000 $ 3,800,000 $ 2,500,000 $ 2,500,000                  
Revenue recognized related to upfront and milestone payments                   700,000 3,500,000      
Deferred revenue               6,400,000   6,400,000   7,100,000    
Non-refundable up-front received period         6 months                  
Non-refundable milestone payment received         $ 3,800,000                  
HLS | Out-licenses | Health Canada                            
License And Collaboration Agreements [Line Items]                            
Non-refundable milestone payment received         2,500,000                  
HLS | Out-licenses | Licensing Revenue                            
License And Collaboration Agreements [Line Items]                            
Licenses revenue                   7,300,000   $ 6,600,000    
HLS | Out-licenses | Product Revenue, Net                            
License And Collaboration Agreements [Line Items]                            
Licenses revenue               $ 8,500,000      
HLS | Out-licenses | Maximum                            
License And Collaboration Agreements [Line Items]                            
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone         $ 50,000,000.0